Public Market Listing
GLENMARK NSE
NSE primary exchange listing
External market data link · No third-party exchange redistribution
Assets (3 total) 3 Total Assets
0 Approved
3 Phase 3 / Filed
0 Phase 1–2 / Early
8 Diseases
Disease: All diseases (3) Non-Small Cell Lung Cancer (3) HIV (1) Chronic Hepatitis B (1) Endometrial Cancer (1) Breast Cancer (1) Ovarian Cancer (1) Colorectal Cancer (1) Gastric Cancer (1)
Stage: All stages (3) Approved / Phase 4 (0) Phase 3 / Filed (3) Phase 2 Phase 1 / Preclinical
Quick filter: All (3) Non-Small Cell Lung Cancer (3) HIV (1) Chronic Hepatitis B (1) Endometrial Cancer (1) Breast Cancer (1)
Showing 3 of 3 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 EGFR Small molecule
Non-Small Cell Lung Cancer
Phase 3 PD-L1 Monoclonal antibody
HIV Non-Small Cell Lung Cancer Chronic Hepatitis B Endometrial Cancer
Phase 3 HER2 Antibody–drug conjugate
Non-Small Cell Lung Cancer Breast Cancer Ovarian Cancer Colorectal Cancer Gastric Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer
Upcoming events (25 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (7) November 2026 (1) December 2026 (6) Envafolimab Phase 1/2 Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma Est. primary completion 2026-12 ·
NCT05024214 ·
CT.gov ↗ What to watch
Envafolimab Phase 2 Advanced Endometrial Cancer Est. primary completion 2026-12 ·
NCT05112991 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 2 HER2 Expression / Amplification in Patients With Biliary Tract Cancer Est. primary completion 2026-12-31 ·
NCT06413745 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 3 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Est. primary completion 2026-12-31 ·
NCT05424835 ·
CT.gov ↗ What to watch
2027 (8) May 2027 (1) June 2027 (1) Trastuzumab rezetecan Phase 3 HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Est. primary completion 2027-06-30 ·
NCT06123494 ·
CT.gov ↗ What to watch
August 2027 (1) Envafolimab Phase 2 Solid Tumor Est. primary completion 2027-08-30 ·
NCT04891198 ·
CT.gov ↗ What to watch
October 2027 (1) Est. primary completion 2027-10 ·
NCT07140393 ·
CT.gov ↗ What to watch
December 2027 (4) Trastuzumab rezetecan Phase 2 HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Est. primary completion 2027-12 ·
NCT05671822 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 2 Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Est. primary completion 2027-12 ·
NCT07102901 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 3 Early-stage or Locally Advanced HER2-positive Breast Cancer Est. primary completion 2027-12 ·
NCT07196774 ·
CT.gov ↗ What to watch
Envafolimab Phase 3 Non-small Cell Lung Cancer Est. primary completion 2027-12-30 ·
NCT06123754 ·
CT.gov ↗ What to watch
2028 (4) March 2028 (1) Trastuzumab rezetecan Phase 3 PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer Est. primary completion 2028-03 ·
NCT07111832 ·
CT.gov ↗ What to watch
May 2028 (1) June 2028 (2) Trastuzumab rezetecan Phase 2 HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer Est. primary completion 2028-06 ·
NCT06778031 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 2 Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer Est. primary completion 2028-06 ·
NCT07497386 ·
CT.gov ↗ What to watch
2029 (2) June 2029 (1) Envafolimab Phase 2 Biliary Tract Neoplasms Est. primary completion 2029-06 ·
NCT04910386 ·
CT.gov ↗ What to watch
September 2029 (1) 2030 (3) April 2030 (1) Trastuzumab rezetecan Phase 3 HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Est. primary completion 2030-04 ·
NCT06126640 ·
CT.gov ↗ What to watch
October 2030 (1) Trastuzumab rezetecan Phase 3 Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma Est. primary completion 2030-10 ·
NCT07118527 ·
CT.gov ↗ What to watch
December 2030 (1) 2031 (1) See the full readout calendar ↗
Regulatory and conference events (1) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
2 July 2026 Filing accepted Trastuzumab rezetecan NMPA accepts the marketing application for trastuzumab rezetecan in HER2-low breast cancer (CXSS2600103), with priority review China, NMPA · Jiangsu Hengrui Pharmaceuticals ·
Source ↗ Financial reports No financial reports recorded.